4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation

Journal of Neurology

Volumn 258, Issue 9, 2011, Pages 1708-1711

  Schniepp, Roman ^a,b   Wuehr, Max ^b   Ackl, Nibal ^a   Danek, Adrian ^a   Brandt, Thomas ^b   Strupp, Michael ^a,b   Jahn, Klaus ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL CACNA 1A; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; CASE REPORT; CEREBELLAR ATAXIA; CHROMOSOME 19P; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE DURATION; GAIT; GENE MUTATION; HUMAN; LETTER; MALE; MIGRAINE; PRIORITY JOURNAL; SPINOCEREBELLAR ATAXIA TYPE 6; TREATMENT OUTCOME; WALKING; WALKING SPEED;

4-AMINOPYRIDINE; AGED; CALCIUM CHANNELS; CEREBELLAR ATAXIA; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MIDDLE AGED; MUTATION; POTASSIUM CHANNEL BLOCKERS;

EID: 80054751973     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5987-z     Document Type: Letter

References (16)

1. K Alvina K Khodakhah 2010 The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia J Neurosci 30 7258 7268 20505092 10.1523/JNEUROSCI.3582-09.2010 1:CAS:528:DC%2BC3cXovVOisL4%3D
2. JM Hausdorff 2005 Gait variability: methods, modeling and meaning J Neuroeng Rehabil 2 19 16033650 10.1186/1743-0003-2-19 (Pubitemid 41185445)
3. JM Hausdorff 2007 Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking Hum Mov Sci 26 555 589 17618701 10.1016/j.humov.2007.05.003 (Pubitemid 47324190)
4. W Ilg H Golla P Thier MA Giese 2007 Specific influences of cerebellar dysfunctions on gait Brain 130 786 798 17287287 10.1093/brain/awl376 (Pubitemid 46410739)
5. K Jahn A Deutschlander T Stephan R Kalla M Wiesmann M Strupp T Brandt 2008 Imaging human supraspinal locomotor centers in brainstem and cerebellum Neuroimage 39 786 792 18029199 10.1016/j.neuroimage.2007.09.047 (Pubitemid 350123716)
6. C Jodice E Mantuano L Veneziano F Trettel G Sabbadini L Calandriello A Francia M Spadaro F Pierelli F Salvi RA Ophoff RR Frants M Frontali 1997 Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p Hum Mol Genet 6 1973 1978 9302278 10.1093/hmg/6.11.1973 1:CAS:528:DyaK2sXmslKiu74%3D (Pubitemid 27460375)
7. M Lohle W Schrempf M Wolz H Reichmann A Storch 2008 Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2-a video case report Mov Disord 23 1314 1316 18442126 10.1002/mds.22071
8. S Mori K Matsuyama F Mori K Nakajima 2001 Supraspinal sites that induce locomotion in the vertebrate central nervous system Adv Neurol 87 25 40 11347228 1:STN:280:DC%2BD3Mris12jsQ%3D%3D
9. LE Powell AM Myers 1995 The Activities-specific Balance Confidence (ABC) Scale J Gerontol A Biol Sci Med Sci 50A M28 M34 7814786 10.1093/gerona/50A.1.M28 1:STN:280:DyaK2M7hsVaqsw%3D%3D
10. T Schmitz-Hubsch ST du Montcel L Baliko J Berciano S Boesch C Depondt P Giunti C Globas J Infante JS Kang B Kremer C Mariotti B Melegh M Pandolfo M Rakowicz P Ribai R Rola L Schols S Szymanski BP van de Warrenburg A Durr T Klockgether R Fancellu 2006 Scale for the assessment and rating of ataxia: development of a new clinical scale Neurology 66 1717 1720 16769946 10.1212/01.wnl.0000219042.60538.92 1:STN:280:DC%2BD28zls1artg%3D%3D (Pubitemid 43964628)
11. M Strupp R Kalla M Dichgans T Freilinger S Glasauer T Brandt 2004 Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine Neurology 62 1623 1625 15136697 1:CAS:528:DC%2BD2cXjt1ylur0%3D (Pubitemid 38608211)
12. M Strupp R Kalla S Glasauer J Wagner K Hufner K Jahn T Brandt 2008 Aminopyridines for the treatment of cerebellar and ocular motor disorders Prog Brain Res 171 535 541 18718350 10.1016/S0079-6123(08)00676-6
13. BP van de Warrenburg JA Steijns M Munneke BP Kremer BR Bloem 2005 Falls in degenerative cerebellar ataxias Mov Disord 20 497 500 15645525 10.1002/mds.20375 (Pubitemid 40779028)
14. ML Walker AG Austin GM Banke SR Foxx L Gaetano LA Gardner J McElhiney K Morris L Penn 2007 Reference group data for the functional gait assessment Phys Ther 87 1468 1477 17785375 10.2522/ptj.20060344 (Pubitemid 350074382)
15. JT Walter K Alvina MD Womack C Chevez K Khodakhah 2006 Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia Nat Neurosci 9 389 397 16474392 10.1038/nn1648 1:CAS:528:DC%2BD28Xhslelsbg%3D (Pubitemid 43290969)
16. L Yardley N Beyer K Hauer G Kempen C Piot-Ziegler C Todd 2005 Development and initial validation of the Falls Efficacy Scale-International (FES-I) Age Ageing 34 614 619 16267188 10.1093/ageing/afi196 (Pubitemid 41700006)